Loading clinical trials...
Loading clinical trials...
Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)
Conditions
Interventions
Pembrolizumab
Lenvatinib
+4 more
Locations
177
United States
UCLA Hematology/Oncology - Santa Monica ( Site 0003)
Los Angeles, California, United States
Georgetown University Medical Center ( Site 0009)
Washington D.C., District of Columbia, United States
James Graham Brown Cancer Center ( Site 0017)
Louisville, Kentucky, United States
Johns Hopkins University ( Site 0052)
Baltimore, Maryland, United States
Dana Farber Cancer Center ( Site 0019)
Boston, Massachusetts, United States
UMASS Memorial Medical Center ( Site 0020)
Worcester, Massachusetts, United States
Start Date
December 30, 2020
Primary Completion Date
October 29, 2024
Completion Date
March 31, 2026
Last Updated
November 28, 2025
Lead Sponsor
Merck Sharp & Dohme LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions